Alkermes

Alkermes

Biotechnology
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

$7.3B

Market Cap • 10/23/2026

2011

(15 years)

Founded

1991

(35 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Ireland

Ireland

Country

Valuation

P/B

4

P/S

4,4

P/EBITDA

40,9

P/OCF

29,1

P/FCF

33

P/E

110,5

BVPS

10,8

EPS

0,4

Market Cap

Market Cap

7,3B

EV

8,2B

EV/Revenue

4,9

EV/EBITDA

46

EV/EBIT

70,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

0%

Total Yield

0%

Payout

0%

Retained Earnings

-800,8M

Profitability

Gross Margin

84,6%

EBITDA Margin

10,7%

EBIT Margin

7%

Net Margin

4%

D&A/EBITDA

19,2%

R&D/Revenue

23,4%

Capex/Revenue

1,8%

Capex/D&A

47,9%

Capex/OCF

11,8%

SBC/OCF

47,1%

% PPE

6,7%

% Goodwill

13,5%

ROE

3,9%

ROIC

4,1%

Growth

CAGR Revenue 5Y

8,7%

CAGR OCF 5Y

16,8%

Leverage

N.D./EBITDA

5,1

Debt/Equity

0%

Current Ratio

2,3

Quick Ratio

1,7

Interest Coverage

198,4%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium